Monday 2 November 2026 Export TWST’s income statement to Excel — free account

Twist Bioscience Corporation

TWST Healthcare Biotechnology

Twist Bioscience Corporation’s revenue for fiscal 2025 (year ended September 2025) was $376.6 million, up 20.3% from fiscal 2024.

Revenue: +23.2%
EPS: −264.7%
Free cash flow: −7.23%
Total debt: 0.00%

Quarter to June 2026, against a year earlier

129.86 22.92 −15.00%

Follow TWST

Alert me

Market cap: $10.1B
P/E: 0.0×
Fwd P/E: −91.4×
Dividend yield: —
F-score: 4/9
Altman Z: 3.44
Beneish M: −2.30
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Filings

Twist Bioscience Corporation 10-K filed Nov 18, 2024

Fiscal year 2024 · Period ended Sep 30, 2024 · Filed Nov 18, 2024 · accepted 4:10 PM ET · Document on sec.gov · Filing index

Red flags

Material weakness Nov 18, 2024
Twist Bioscience Corporation’s 10-K reports a material weakness in internal control over financial reporting

changes related to the remediation of the previously identified material weakness noted above

10-K filed Nov 18, 2024 · The filing · sec.gov